An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 14, Pages 1467-1476
Publisher
Informa UK Limited
Online
2017-09-12
DOI
10.1080/14656566.2017.1378346
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- mRECIST for systemic therapies: More evidence is required before recommendations can be made
- (2017) Julien Edeline et al. JOURNAL OF HEPATOLOGY
- Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
- (2017) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Liver sinusoidal endothelial cells: Physiology and role in liver diseases
- (2017) Johanne Poisson et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib
- (2017) Tim Meyer et al. LIVER INTERNATIONAL
- Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration
- (2016) Wenting Ma et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
- (2016) Riccardo Lencioni et al. JOURNAL OF HEPATOLOGY
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Olivier Mir et al. LANCET ONCOLOGY
- Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
- (2016) Joleen M. Hubbard et al. Targeted Oncology
- The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro
- (2015) Véronique Descamps et al. ANTIVIRAL RESEARCH
- Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
- (2015) M. Ikeda et al. CLINICAL CANCER RESEARCH
- Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma
- (2015) ZhengGang Ren et al. JOURNAL OF CLINICAL ONCOLOGY
- SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
- (2015) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
- (2015) Calin Cainap et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
- (2015) Jordi Bruix et al. LANCET ONCOLOGY
- Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
- (2015) Tung-Hung Su et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo
- (2015) Matthias Pinter et al. RADIOLOGY
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial
- (2014) Masatoshi Kudo et al. HEPATOLOGY
- A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma
- (2014) Jennifer J. Knox et al. INVESTIGATIONAL NEW DRUGS
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- (2014) Andrew X. Zhu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systemic therapy in HCC: Lessons from brivanib
- (2014) David Bolos et al. JOURNAL OF HEPATOLOGY
- HCC therapies—lessons learned
- (2014) Marcus-Alexander Wörns et al. Nature Reviews Gastroenterology & Hepatology
- Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma
- (2014) Jean-Luc Raoul et al. Liver Cancer
- Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort
- (2013) S. Schlesinger et al. ANNALS OF ONCOLOGY
- A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2013) A. X. Zhu et al. CLINICAL CANCER RESEARCH
- Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
- (2013) Jordi Bruix et al. EUROPEAN JOURNAL OF CANCER
- Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
- (2013) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
- (2013) Josep M. Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma
- (2013) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- (2013) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats
- (2012) M. D'Amico et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2012) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
- (2012) Ann-Lii Cheng et al. EUROPEAN JOURNAL OF CANCER
- Vandetanib in patients with inoperable hepatocellular carcinoma: A phase II, randomized, double-blind, placebo-controlled study
- (2012) Chiun Hsu et al. JOURNAL OF HEPATOLOGY
- Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses
- (2012) Jean-Luc Raoul et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma
- (2011) Weijing Sun et al. CANCER
- Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
- (2011) Julien Edeline et al. CANCER
- Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
- (2011) J.-W. Park et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
- (2011) T. Yau et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
- (2011) Sergio Bracarda et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
- (2011) Masatoshi Kudo et al. EUROPEAN JOURNAL OF CANCER
- Role of Differentiation of Liver Sinusoidal Endothelial Cells in Progression and Regression of Hepatic Fibrosis in Rats
- (2011) Guanhua Xie et al. GASTROENTEROLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma
- (2010) C-H Hsu et al. BRITISH JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Hepatocellular Carcinoma (HCC)
- (2010) Peter Ferenci et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: New targets for the treatment of portal hypertension?
- (2010) Dominique Thabut et al. JOURNAL OF HEPATOLOGY
- Angiogenesis in chronic liver disease and its complications
- (2010) Stephanie Coulon et al. LIVER INTERNATIONAL
- The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases
- (2010) R. S. Bhide et al. MOLECULAR CANCER THERAPEUTICS
- Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
- (2010) D. Koeberle et al. ONCOLOGIST
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Review article: the management of hepatocellular carcinoma
- (2009) R. CABRERA et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication
- (2009) K. Himmelsbach et al. GUT
- Antiangiogenic therapy: Not just for cancer anymore?
- (2009) Vijay H. Shah et al. HEPATOLOGY
- Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma
- (2009) Melanie B. Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
- (2008) Michael C. Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search